Records containing: Herpes Simplex Virus Infection
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2024-02-29NOWDx Test for the Diagnosis of Herpes Simplex Virus Type 2
-
CLINICAL_TRIALS study record update · 2022-12-28Host RNA Expression Profiles and Protein Biomarkers in Neonatal Herpes Simplex Virus Infection
-
CLINICAL_TRIALS study record update · 2022-08-24CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy Assisted Corneal Transplantation in the Treatment of Refractory Viral Keratitis
-
CLINICAL_TRIALS study record update · 2021-06-10Pharmacokinetics of a New Paediatric Formulation of Valacyclovir Used for Prophylaxis and Treatment of Varicella Zoster Virus (VZV) and Herpes Simplex Virus (HSV) Infections in Children, Phase II (VALID II)
-
CLINICAL_TRIALS study record update · 2021-01-19Oral and Perioral Herpes Simplex Virus Infection Type I in a Five-month-old Infant: A Case Report
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2020-12-08Bioequivalence Study in Healthy Volunteers of a New Paediatric Formulation of Valacyclovir Used for Prophylaxis and Treatment of VZV and HSV Infections in Children, Phase I (VALID-I)
-
CLINICAL_TRIALS study record update · 2020-12-07Palatability Testing of a New Paediatric Formulation of Valacyclovir for the Prophylaxis and Treatment of VZV and HSV Infections in Children
-
CLINICAL_TRIALS study record update · 2019-04-18A Phase I, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Subcutaneous Dose of UB-621 in Healthy Volunteers